Calibrating COVID-19: The Interplay of Disease Modifying Therapy and Vaccination in Patients with Multiple Sclerosis

Calibrating COVID-19: The Interplay of Disease Modifying Therapy and Vaccination in Patients with Multiple Sclerosis

Calibrating COVID-19: The Interplay of Disease Modifying Therapy and Vaccination in Patients with Multiple Sclerosis

COVID-19 vaccination isn’t as straightforward for patients with MS on immunosuppressive therapies. Here’s what the National MS Society recommends.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The emergence of COVID-19 has created an unprecedented medical emergency that both raises new questions and presents updated information each day. This issue is even more pressing for patients with conditions such as multiple sclerosis (MS) who have altered immune systems from both chronic illness and disease modifying therapies (DMTs). While the advent of vaccines has revived hope for a return to normal life, vaccination is not always straightforward for those on or planning to start immunosuppressive therapies such as MS DMT. In this activity, Drs. Claire Riley and Robert Bermel discuss guidance outlined by the National Multiple Sclerosis Society (NMSS) and approaches to implementing these considerations in routine practice.

  • Disclosure of Conflicts of Interest


    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Planners' and Managers' Disclosure 

    PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

    Faculty Disclosures:

    Dr. Bermel reported the following financial relationships:

    • Patent holder: Multiple Sclerosis Performance Test
    • Consulting fees: Biogen, EMD Serono, Genentech/Roche, Genzyme/Sanofi, Novartis, Viela Bio
    • Contracted research: Biogen, Genentech/Roche, Novartis

    Dr. Riley reported the following financial relationships:

    • Consulting Fees: Bristol-Myers Squibb, Genentech

    Dr. Subei reported no relevant financial relationships.

  • Target Audience

    The target audience for this CME initiative includes general neurologists and neurodegenerative disease specialists, and advanced practice professionals involved in the diagnosis and long-term management of patients with MS.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Review historical data on the interaction of DMT with multiple vaccine types in order to assess the applicability of these observations to the COVID-19 pandemic.
    2. Identify how receipt of a COVID-19 vaccination may influence the initiation of MS DMT to determine whether the start and/or dosing of each agent requires adjustment.
    3. Examine how distinct mechanisms of active MS DMT may influence the ability to receive a COVID-19 vaccine, and determine whether any agents require a washout period prior to its administration.
  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    Accreditation Statement
    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Designation Statement
    PIM designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • Provider(s)/Educational Partner(s)

    This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC. 

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This activity is supported by educational grants from Bristol-Myers Squibb, Genentech, and Sanofi.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free